Table 4 List of miRNAs that met initial eligibility criteriaa for inclusion in predictive models.

From: Prenatal opioid-exposed infant extracellular miRNA signature obtained at birth predicts severity of neonatal opioid withdrawal syndrome

miRNA

Pharmacologic treatment

LOS ≥ 14 Days

Difference1

Mean (SD)

Cohen's d2

Difference3

Mean (SD)

Cohen's d2

miRNAs which met initial eligibility criteria for both outcomes

hsa-let-7b-5p

− 0.77 (0.88)*

0.88

− 1.13 (0.81)*

1.40

hsa-miR-125a-5p

− 0.73 (1.24)*

0.59

− 0.86 (1.22)*

0.70

hsa-miR-128-3p

0.41 (0.64)*

0.64

0.54 (0.62)*

0.86

hsa-miR-154-5p

0.62 (0.85)*

0.72

0.60 (0.86)*

0.69

hsa-miR-18b-5p

0.53 (0.74)*

0.71

0.64 (0.73)*

0.87

hsa-miR-21-5p

− 0.27 (0.59)†

0.47

− 0.43 (0.57)*

0.76

hsa-miR-23a-3p

− 0.47 (0.81)*

0.58

− 0.59 (0.80)*

0.74

hsa-miR-23b-3p

− 0.40 (0.77)†

0.52

− 0.51 (0.76)*

0.67

hsa-miR-24-3p

− 0.37 (0.85)†

0.44

− 0.52 (0.84)*

0.62

hsa-miR-27b-3p

− 0.34 (0.70)*

0.49

− 0.54 (0.67)*

0.81

hsa-miR-29a-3p

− 1.01 (1.30)*

0.78

− 1.24 (1.26)*

0.99

hsa-miR-29c-3p

− 0.62 (1.11)†

0.56

− 0.75 (1.09)*

0.68

hsa-miR-30a-5p

− 0.73 (0.91)*

0.80

− 0.98 (0.87)*

1.13

hsa-miR-30c-5p

− 0.28 (0.50)†

0.55

− 0.31 (0.50)*

0.63

hsa-miR-362-3p

0.92 (1.62)*

0.57

1.19 (1.59)*

0.74

hsa-miR-365a-3p

− 0.91 (1.50)*

0.61

− 1.21 (1.46)*

0.83

hsa-miR-382-5p

0.59 (0.95)†

0.63

0.60 (0.95)†

0.63

hsa-miR-421

0.91 (0.86)*

1.06

0.86 (0.87)*

0.98

hsa-miR-423-3p

0.26 (0.49)†

0.53

0.27 (0.49)†

0.55

hsa-miR-423-5p

0.28 (0.43)*

0.65

0.25 (0.43)†

0.58

hsa-miR-484

0.39 (0.54)*

0.72

0.40 (0.54)*

0.74

hsa-miR-495-3p

0.46 (1.01)†

0.46

0.61 (1.00)*

0.61

hsa-miR-584-5p

0.54 (0.75)*

0.73

0.48 (0.76)*

0.64

hsa-miR-629-5p

0.77 (1.29)†

0.59

0.77 (1.30)*

0.59

hsa-miR-652-3p

0.40 (0.58)*

0.70

0.50 (0.56)*

0.90

miRNAs which met initial eligibility criteria for pharmacologic treatment

hsa-let-7d-5p

− 0.65 (1.01)†

0.65

− 0.52 (1.03)

0.51

hsa-miR-133b

− 0.92 (1.81)†

0.51

− 0.89 (1.81)

0.49

hsa-miR-146b-5p

− 0.75 (0.93)*

0.80

− 0.47 (0.97)

0.49

hsa-miR-152-3p

0.25 (0.46)*

0.53

0.19 (0.47)

0.42

hsa-miR-186-5p

0.36 (0.72)†

0.50

0.37 (0.73)

0.51

hsa-miR-18a-5p

0.43 (0.77)*

0.56

0.35 (0.78)

0.45

hsa-miR-223-5p

− 1.06 (2.02)†

0.52

− 0.02 (2.08)

0.01

hsa-miR-320d

0.27 (0.54)†

0.50

0.19 (0.55)

0.34

hsa-miR-324-5p

0.99 (2.30)*

0.43

0.11 (2.34)

0.05

hsa-miR-543

1.30 (3.18)*

0.41

1.23 (3.19)†

0.39

miRNAs which met initial eligibility criteria for LOS ≥ 14 Days

hsa-let-7e-5p

− 0.39 (0.72)

0.53

− 0.54 (0.71)*

0.77

hsa-miR-103a-3p

0.18 (0.74)

0.25

0.41 (0.72)†

0.57

hsa-miR-10b-5p

− 0.25 (0.92)

0.28

− 0.59 (0.89)*

0.66

hsa-miR-125b-5p

− 0.40 (1.15)

0.35

− 0.67 (1.12)*

0.60

hsa-miR-127-3p

0.32 (0.95)

0.33

0.51 (0.94)†

0.54

hsa-miR-146a-5p

0.24 (0.83)

0.30

0.48 (0.81)†

0.59

hsa-miR-191-5p

0.08 (0.56)

0.14

0.30 (0.55)*

0.54

hsa-miR-27a-3p

− 0.36 (0.82)

0.44

− 0.51 (0.81)*

0.63

hsa-miR-328-3p

− 0.17 (0.75)

0.23

− 0.49 (0.73)†

0.67

hsa-miR-34a-5p

− 0.21 (1.23)

0.17

− 0.55 (1.21)†

0.46

hsa-miR-376c-3p

0.43 (1.04)

0.41

0.52 (1.03)†

0.50

hsa-miR-409-3p

0.49 (1.04)

0.47

0.77 (1.01)*

0.76

hsa-miR-425-3p

0.33 (0.90)

0.37

0.46 (0.89)†

0.52

hsa-miR-505-3p

0.13 (0.76)

0.18

0.38 (0.74)*

0.51

hsa-miR-532-5p

0.33 (0.71)

0.46

0.39 (0.71)†

0.55

hsa-miR-99a-5p

− 0.33 (0.92)

0.36

− 0.61 (0.89)*

0.69

  1. Final model miRNAs were identified through the stepwise logistic regression modelling and are shown in italics.
  2. CT cycle threshold, ΔCT normalized cycle threshold, LOS length of hospital stay, SD standard deviation.
  3. aCriteria included: p < 0.10 for the differences in miRNA expression and d > 0.40 for mean difference in miRNA expression in unadjusted analyses.
  4. 1ΔΔCT [(− ΔCTPharmacologically-Treated) − (− ΔCTNot-Pharmacologically-Treated)].
  5. 2Effect size shown as absolute value.
  6. 3ΔΔCT [(− ΔCTLOS ≥ 14 days) − (− ΔCTLOS < 14 days)].
  7. *p < 0.05; †p < 0.10.
Back to article page